NCT05424250 is a NA clinical trial of occasional aversive imagination in Spider Fear, sponsored by Philipps University Marburg.

Who is sponsoring NCT05424250?

NCT05424250 is sponsored by Philipps University Marburg.

What drugs are being tested in NCT05424250?

Interventions in NCT05424250: occasional aversive imagination, Exposure.

What condition does NCT05424250 study?

NCT05424250 studies Spider Fear, Arachnophobia.

Is NCT05424250 still recruiting?

NCT05424250 is currently completed. Last updated 9 January 2026.

Last reviewed 2026-01-09 · How we verify

NCT05424250

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optimizing Exposure Using Occasional Aversive Imagery in Spider Fearful Individuals

Completed NA Last updated 9 January 2026

What this trial tests

NA trial testing occasional aversive imagination in Spider Fear in 67 participants. Completed in 30 September 2023.

Timeline

15 June 2022

Primary endpoint
31 July 2023

30 September 2023

Quick facts

Lead sponsor	Philipps University Marburg
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	67
Start date	15 June 2022
Primary completion	31 July 2023
Estimated completion	30 September 2023
Sites	1 location across Germany

Drugs / interventions tested

occasional aversive imagination
Exposure

Conditions studied

Spider Fear — all drugs for Spider Fear →
Arachnophobia — all drugs for Arachnophobia →

Sponsor

Philipps University Marburg

Who can join

18 and older, any sex, with Spider Fear or Arachnophobia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The effectiveness of an optimized extinction training is investigated in spider-fearful individuals. Participants will undergo a one-session standardized extinction training, either with or without occasional metal imagination of most feared apprehension towards spiders. The effectiveness of the training is measured by symptom improvement according to subjective ratings and behavioural avoidance tests one week later.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Philipps University Marburg trials

Trials by the same sponsor.

NCT07498803 — Sota-ES - Sotatercept in Patients With Congenital Heart Disease and Eisenmenger´s Syndrome · Phase 2 · not yet recruiting
NCT07388004 — Group Therapy for Major Depression: Comparing Expectation-Focused and Reward-Focused Psychotherapy Approaches · NA · recruiting
NCT07166692 — Evaluation of a Retrieval Augmented Large Language Model as a Diagnostic Copilot in Rheumatology · NA · completed
NCT06865534 — Large Language Models to Aid Gynecological Oncology Treatment · NA · recruiting
NCT06968897 — Neurological Development In Toddlers After Maternal SARS-CoV-2 Infection During Pregnancy · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05424250 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Philipps University Marburg
Last refreshed: 9 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05424250.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing